Xenon director granted RSUs, options and shares

Q: How many Restricted Share Units did Patrick Machado receive from Xenon Pharmaceuticals (XENE)?

Machado received 1,593 Restricted Share Units on June 3, 2026. Each RSU represents a contingent right to receive one Common Share, vesting 100% on the earlier of June 1, 2027 or the day before Xenon Pharmaceuticals’ 2027 annual meeting of shareholders.

Xenon Pharmaceuticals Inc. director Patrick Machado reported multiple equity awards and an option exercise.

Accepted by SEC EDGAR 06/03/2026 - 09:04 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Xenon Pharmaceuticals Inc. director Patrick Machado reported multiple equity awards and an option exercise. On June 1, 2026, 2,645 Restricted Share Units (RSUs) vested, converting into 2,645 Common Shares, all held directly. On June 3, 2026, he received 1,593 additional RSUs and an option grant for 10,507 shares with a $53.4600 exercise price, expiring on June 2, 2036. The newly granted RSUs and options are scheduled to vest or become exercisable in connection with the issuer’s 2027 annual meeting of shareholders.

Insider Trade Summary

2,645 shares exercised/converted

Exercise 4 txns

Insider Machado Patrick

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	10,507	$0.00	$0.00
Grant/Award	Restricted Share Units	1,593	$0.00	$0.00
Exercise	Restricted Share Units	2,645	$0.00	$0.00
Exercise	Common Shares	2,645	$0.00	$0.00

Holdings After Transaction: Share Option (Right to Buy) — 10,507 contracts (Direct); Restricted Share Units — 1,593 contracts (Direct); Common Shares — 2,645 shares (Direct)

Holdings Before and After: Share Option (Right to Buy), 0 to 10,507 contracts (Direct); Restricted Share Units, 2,645 to 1,593 contracts (Direct); Common Shares, 0 to 2,645 shares (Direct)

Footnotes (3)

F1. Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.
F2. Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.
F3. Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

Key Figures

RSUs granted: 1,593 RSUs Options granted: 10,507 options Option exercise price: $53.4600 per share +3 more

6 metrics

RSUs granted 1,593 RSUs Awarded June 3, 2026; vesting by 2027 annual meeting

Options granted 10,507 options Granted June 3, 2026; right to buy Common Shares

Option exercise price $53.4600 per share Exercise price for 10,507-share option grant

Option expiration June 2, 2036 Expiration date of the 10,507-share option grant

RSUs exercised 2,645 RSUs Converted to Common Shares on June 1, 2026

Common Shares after exercise 2,645 shares Directly held following RSU vesting on June 1, 2026

Key Terms

Restricted Share Units, Share Option (Right to Buy), exercise or conversion of derivative security, annual meeting of shareholders

4 terms

exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

annual meeting of shareholders financial

"the day before the date of the issuer's 2027 annual meeting of shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Xenon Pharmaceuticals (XENE) report for Patrick Machado?

Xenon Pharmaceuticals reported that director Patrick Machado received new RSU and option grants and exercised RSUs into Common Shares. The filing shows only equity awards and a derivative exercise, with no open-market share purchases or sales disclosed in these transactions.

What are the details of Patrick Machado’s option grant at Xenon Pharmaceuticals (XENE)?

Machado was granted options for 10,507 Common Shares at an exercise price of $53.4600 per share. These options were awarded on June 3, 2026 and expire on June 2, 2036, with vesting tied to the timing of the company’s 2027 annual shareholder meeting.

Did Patrick Machado exercise any equity awards at Xenon Pharmaceuticals (XENE)?

Yes. On June 1, 2026, 2,645 Restricted Share Units were exercised, converting into 2,645 Common Shares. These RSUs had been granted on June 5, 2025 and vested 100% the day before Xenon Pharmaceuticals’ 2026 annual meeting of shareholders.

How many Xenon Pharmaceuticals (XENE) Common Shares does Patrick Machado hold after these transactions?

Following the June 1, 2026 RSU vesting and conversion, Machado holds 2,645 Common Shares directly. Separately, he also holds 1,593 RSUs and options for 10,507 Common Shares, reflecting equity incentives tied to future vesting and exercise conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Machado Patrick

(Last)

(First)

(Middle)

3650 GILMORE WAY

(Street)

BURNABY

BRITISH COLUMBIA, CANADA

V5G 4W8

(City)

(State)

(Zip)

BRITISH COLUMBIA, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Xenon Pharmaceuticals Inc. [ XENE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Shares	06/01/2026		M		2,645⁽¹⁾	A	⁽¹⁾	2,645	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Share Units	⁽¹⁾	06/01/2026		M			2,645	⁽¹⁾	⁽¹⁾	Common Shares	2,645	$0	0	D
Share Option (Right to Buy)	$53.46	06/03/2026		A		10,507		⁽²⁾	06/02/2036	Common Shares	10,507	$0	10,507	D
Restricted Share Units	$0	06/03/2026		A		1,593		⁽³⁾	⁽³⁾	Common Shares	1,593	$0	1,593	D

Explanation of Responses:

1. Represents Common Shares earned and vested under a restricted share unit ("RSU") award granted to the reporting person on June 5, 2025. The RSU award vested 100% on June 1, 2026, the day before the date of the issuer's 2026 annual meeting of shareholders.

2. Vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

3. Each RSU represents a contingent right to receive one Common Share vesting 100% on the earlier of (i) June 1, 2027 or (ii) the day before the date of the issuer's 2027 annual meeting of shareholders.

	/s/ Nathaniel Adams, Attorney-in-fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR